NasdaqHealth CareHealth Care ServicesS&P SmallCap 600
$29.82
+1.05 (+3.65%)
Close of Nov 06, 2026 · end-of-day data
SDGR 8-K filings, explained
Every material Form 8-K Schrödinger has filed with the SEC since November 12, 2024, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Schrödinger reported third-quarter 2026 total revenue of $64.5 million, up 19%, and raised its full-year 2026 ACV and drug discovery revenue guidance. The net loss widened to $37.7 million from $32.8 million, and the company corrected a American Society of Hematology abstract that wrongly described an ongoing SGR-1505 combination study. Shareholders see a higher top line and outlook alongside a larger loss.
Total revenue was $64.5 million, up from $54.3 million, with drug discovery revenue of $24.2 million helped by a Structure Therapeutics milestone payment.
Net loss was $37.7 million, or $0.50 per share, compared with a net loss of $32.8 million, or $0.45 per share, a year earlier.
2026 ACV guidance was raised to $222 million to $232 million, and drug discovery revenue guidance to $75 million to $85 million.
The company said it has not started a combination study of SGR-1505 under its FDA-cleared protocol and is exploring strategic opportunities for the program.
Schrödinger reported second quarter 2026 total revenue of $58.9 million, up 8%, and net income of $6.0 million, compared with a net loss of $43.2 million a year earlier. Net income was helped by a $45.9 million change in fair value of equity investments, and the company raised its 2026 drug discovery revenue guidance to $65 million to $75 million, though software revenue fell 10%.
Total revenue was $58.9 million, up 8% from $54.8 million; diluted EPS was $0.08 versus a loss of $0.59 per share.
Software revenue was $32.5 million, down 10%, which the company attributed to its transition to hosted software licensing.
2026 drug discovery revenue guidance was raised to $65 million to $75 million from $55 million to $65 million, tied to a $10 million Ajax Therapeutics collaboration milestone.
2026 ACV guidance is $218 million to $228 million, representing 10% to 15% growth over 2025.
At its June 22, 2026 annual meeting, Schrodinger stockholders approved an amendment adding 3,000,000 shares to the 2022 Equity Incentive Plan. They also re-elected three Class III directors for terms ending at the 2029 annual meeting, approved an advisory vote on executive compensation, and ratified KPMG LLP as the auditor for fiscal 2026. The added share pool gives the company more shares for equity awards, which can dilute existing holders.
Equity plan: 3,000,000 additional shares authorized; common stock votes were 32,257,903 FOR and 10,825,547 AGAINST
Directors elected: Richard A. Friesner, Rosana Kapeller-Libermann and Gary Sender, each for a term expiring at the 2029 annual meeting
Executive compensation: non-binding advisory vote approved, with 51,345,375 total shares FOR and 870,926 AGAINST
Auditor: KPMG LLP ratified for the fiscal year ending December 31, 2026, with 61,674,114 total shares FOR and 179,559 AGAINST
Schrodinger, Inc. disclosed a June 5, 2026 separation agreement with Mannix Aklian, its former Chief Commercial Officer and Global Head of Software Sales and Marketing. The agreement confirms severance payments and benefits that are substantially comparable to those in his prior employment agreement and the company's severance plan, with a gross bonus amount of $88,096 across three bonus components. For shareholders, the filing describes a routine executive departure with defined costs and a mutual release of claims.
Separation Agreement dated June 5, 2026, between the company and Mannix Aklian, subject to a seven-day revocation period
Salary continuation for nine months and COBRA premium support for 12 months after separation
Bonus payments for Q1 2026, prorated Q2 2026, and prorated 2026 annual bonus total $88,096 gross, plus acceleration of a July 2026 restricted stock unit vesting
Schrodinger said its Chief Commercial Officer, Global Head of Software Sales and Marketing, Mannix Aklian, left the role effective immediately on May 18, 2026, and that Paul Davie, a former executive vice president of sales, is returning as interim replacement while a permanent successor is sought. The company also reaffirmed its full-year and second-quarter 2026 guidance from its May 5, 2026 first-quarter earnings release, which keeps the outlook it previously gave shareholders in place.
Mannix Aklian ceased to serve as Chief Commercial Officer on May 18, 2026, effective immediately.
Paul Davie returns as interim Chief Commercial Officer while the company searches for a permanent replacement.
The company reaffirmed full-year 2026 and second-quarter 2026 guidance from its May 5, 2026 earnings release.
Schrödinger reported first quarter 2026 results with total revenue of $58.6 million, down 2% from a year earlier, and a net loss of $60.0 million compared with $59.8 million. Annual contract value (ACV) grew 12% to $28.4 million, while the company kept its full-year 2026 guidance unchanged, including ACV of $218 million to $228 million.
Total revenue was $58.6 million, down 2%. Software revenue fell 21% to $35.6 million as the company accelerates its shift to hosted licensing, while drug discovery revenue rose to $22.9 million from $10.2 million.
ACV was $28.4 million, up 12%, and $201 million on a trailing four-quarter basis.
Full-year 2026 guidance was maintained: ACV of $218 million to $228 million and drug discovery revenue of $55 million to $65 million.
Cash, cash equivalents, restricted cash and marketable securities totaled $406 million at March 31, 2026.
Schrodinger's board designated Therese Abrams, its Vice President and Corporate Controller, as principal accounting officer effective March 8, 2026. Jenny Herman, the former Chief Accounting Officer and principal accounting officer, transitioned from that role on March 6, 2026, and will stay employed through April 10, 2026 to ensure a smooth handover. This is an administrative change in the finance team that does not alter reported results or guidance.
Therese Abrams, 42, a certified public accountant, was designated principal accounting officer effective March 8, 2026
Abrams has served as Vice President, Corporate Controller since July 2025 and has been with the company since 2013
Jenny Herman transitioned from Chief Accounting Officer and principal accounting officer on March 6, 2026
Herman remains employed through April 10, 2026 to ensure a smooth transition
Schrödinger reported fourth-quarter and full-year 2025 results, with full-year total revenue up 23.3% and net loss narrowing from $187.1 million to $103.3 million. Fourth-quarter total revenue fell 1.2%, and the company said it is accelerating a shift to ratable hosted software revenue that it expects to reduce reported software revenue in the short to medium term.
Full-year 2025 total revenue was $255.9 million, up 23.3%; software revenue was $199.5 million, up 10.6%.
Fourth-quarter 2025 total revenue was $87.2 million, down 1.2%; fourth-quarter net income was $32.5 million versus a net loss of $40.2 million a year earlier.
2026 outlook calls for software ACV of $218 million to $228 million and drug discovery revenue of $55 million to $65 million.
The company targets positive adjusted EBITDA by the end of 2028.
Schrödinger reported third-quarter 2025 total revenue of $54.3 million, up 54% from a year earlier, and a net loss of $32.8 million, narrower than the $38.1 million loss in the prior-year quarter. The company lowered its full-year 2025 software revenue growth guidance to 8% to 13% from 10% to 15%, and said it expects savings of approximately $70 million from expense-reduction measures and a shift away from independent clinical development.
Q3 total revenue was $54.3 million, up 54%; software revenue was $40.9 million, up 28%, and drug discovery revenue was $13.5 million versus $3.4 million a year earlier.
Full-year 2025 software revenue growth guidance was cut to 8% to 13% from 10% to 15%, while drug discovery revenue guidance was raised to $49 million to $52 million from $45 million to $50 million.
Q3 net loss was $32.8 million, versus $38.1 million in Q3 2024; non-GAAP net loss was $42.3 million.
Cash, cash equivalents, restricted cash and marketable securities totaled $401.0 million at September 30, 2025.
Schrodinger entered a separation agreement dated September 5, 2025 with Geoffrey Porges, its former Executive Vice President and Chief Financial Officer, after his previously disclosed departure. The agreement sets out severance payments and benefits that are described as substantially comparable to those in his prior employment agreement and the company's severance plan, with a mutual release of claims. The filing does not name a replacement CFO.
Separation agreement with Dr. Porges dated September 5, 2025, with payments conditioned on a seven-day revocation period
Salary continuation for nine months, and company-paid COBRA premium coverage for 12 months
Schrödinger reported second-quarter 2025 total revenue of $54.8 million, up 16% from a year earlier, and a net loss of $43.2 million, narrower than the $54.0 million loss in the second quarter of 2024. The company kept its 2025 revenue growth guidance and lowered its operating expense outlook, though software gross margin fell to 68% from 80%.
Total revenue rose 16% to $54.8 million from $47.3 million; software revenue rose 15% to $40.5 million.
Net loss was $43.2 million versus $54.0 million a year earlier; software gross margin fell to 68% from 80%.
Software revenue growth guidance of 10% to 15% and drug discovery revenue guidance of $45 million to $50 million were reaffirmed; operating expense guidance was lowered and 2025 operating expenses are now expected to be lower than 2024.
Schrodinger appointed Richie Jain, previously its senior vice president of strategic finance, as executive vice president and chief financial officer effective May 16, 2025. The company said CFO Geoffrey Porges is leaving the role to pursue other opportunities, and he will stay on as an advisor through June 6, 2025 to support the transition.
Richie Jain appointed CFO and Treasurer effective May 16, 2025; base salary $535,000
Jain eligible for a 2025-only target bonus of up to 55% of annualized base salary, prorated
Company expects to grant Jain an option on up to 18,750 shares and 9,375 restricted stock units
Geoffrey Porges separates from CFO role; remains employed as advisor through June 6, 2025
Schrödinger reported first-quarter 2025 total revenue of $59.6 million, up 63% from $36.6 million a year earlier, led by software revenue of $48.8 million. The net loss widened to $59.8 million from $54.7 million, and the loss per share was $0.82 compared with $0.76. The company maintained its previously issued 2025 financial guidance.
Total revenue rose 63% to $59.6 million; software revenue rose 46% to $48.8 million, partly due to early renewals by large customers.
Net loss was $59.8 million versus $54.7 million a year earlier; loss per share was $0.82 versus $0.76.
Non-GAAP net loss was $46.7 million versus $62.4 million in the first quarter of 2024.
Full-year 2025 guidance was maintained, including software revenue growth of 10% to 15% and drug discovery revenue of $45 million to $50 million.
Schrodinger's board elected Bridget van Kralingen as a director effective March 7, 2025, filling a seat on the board. She brings a background in technology and financial services, having previously held senior roles at IBM and Deloitte Consulting and currently serving as a Senior Partner at Motive Partners.
Board elected Bridget van Kralingen as a class II director effective March 7, 2025, with a term expiring at the 2025 annual meeting
She will receive a nonqualified stock option for 17,050 shares at an exercise price of $21.02 and restricted stock units for 10,000 shares under the non-employee director compensation policy
She will sign the company's standard indemnification agreement, which may require the company to cover certain expenses and judgments tied to her board service
Schrödinger reported fourth-quarter and full-year 2024 results and gave 2025 guidance. Full-year total revenue fell 4.2% to $207.5 million, with software revenue up 13.3% and drug discovery revenue down 53%, and the company posted a $187.1 million net loss after 2023 net income of $40.7 million. For shareholders, the results mix growing software sales and a higher fourth-quarter revenue total with wider losses and a sharply lower drug discovery contribution.
Full-year software revenue rose 13.3% to $180.4 million, while drug discovery revenue fell 53% to $27.2 million.
Full-year net loss was $187.1 million, compared with net income of $40.7 million in 2023; 2023 included a $147.2 million gain on equity investments.
Fourth-quarter total revenue rose 19.1% to $88.3 million, but the fourth-quarter net loss widened to $40.2 million from $30.7 million.
For 2025, the company expects software revenue growth of 10% to 15% and drug discovery revenue of $45 million to $50 million.
Schrödinger reported third-quarter 2024 total revenue of $35.3 million, down from $42.6 million a year earlier, while software revenue rose 10%. The net loss narrowed to $38.1 million from $62.0 million, mainly due to changes in the fair value of equity investments, and the company raised the low end of its 2024 software revenue growth guidance. The company also said Novartis will pay $150 million upfront under a new collaboration.
Total revenue fell 17% to $35.3 million; software revenue rose 10% to $31.9 million, while drug discovery revenue fell to $3.4 million from $13.7 million.
Software gross margin decreased to 73% from 76%; operating expenses rose to $86.2 million from $79.8 million.
2024 software revenue growth guidance is now 8% to 13%; drug discovery revenue guidance is $20 million to $30 million.
Novartis will pay Schrödinger $150 million upfront under a multi-target collaboration announced November 12, 2024.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Schrödinger filing is on SEC EDGAR ↗. 8-K briefs of other companies →